Founded with a mission to revolutionize pregnancy health, Mirvie is pioneering the development of the first non-invasive RNA test designed for early detection of pregnancy complications. Their innovative approach aims to address issues that affect 45 million women globally by providing a personalized window into pregnancy. Mirvie's core products focus on predicting and managing conditions such as preeclampsia and preterm birth, offering clinicians valuable tools to improve maternal and fetal outcomes.
Mirvie has garnered attention through landmark research published in prestigious journals like Nature and the American Journal of Obstetrics and Gynecology (AJOG). The company is supported by a team of experts dedicated to advancing maternal health. Notable achievements include the development of comprehensive care plans for conditions like preeclampsia, significantly impacting clinical practices. By bringing pregnancy health into the spotlight, Mirvie is making strides in preventive care and enhancing the well-being of mothers and their babies worldwide.
